The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan

Background: This study aimed to evaluate the cost-effectiveness of treating transplant-ineligible myeloma patients with either a bortezomib plus thalidomide plus dexamethasone (VTD) or a bortezomib plus melphalan plus prednisolone (VMP) treatment in Taiwan. Methods: Newly diagnosed, transplant-ineli...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Jeng-Shiun, Kuo, Yi-Chun, Shi, Hon-Yi, Wang, Ming-Chung, Wang, Li-Ying, Chuang, Tzer-Ming, Ke, Ya-Lun, Yeh, Tsung-Jang, Gau, Yu-Ching, Wang, Hui-Ching, Cho, Shih-Feng, Hsiao, Samuel Yien, Liu, Yi-Chang, Hsu, Chin-Mu, Hsiao, Hui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880219/
https://www.ncbi.nlm.nih.gov/pubmed/35207619
http://dx.doi.org/10.3390/jpm12020130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880219/
https://www.ncbi.nlm.nih.gov/pubmed/35207619
http://dx.doi.org/10.3390/jpm12020130

Ejemplares similares